Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

33.87
+0.02000.06%
Post-market: 33.870.00000.00%19:06 EDT
Volume:1.41M
Turnover:47.66M
Market Cap:6.44B
PE:-11.76
High:34.30
Open:33.54
Low:33.37
Close:33.85
Loading ...

BridgeBio price target raised to $45 from $42 at BofA

TIPRANKS
·
25 Nov 2024

BridgeBio Pharma (BBIO) Receives a Buy from Piper Sandler

TIPRANKS
·
25 Nov 2024

BridgeBio Pharma Inc : Scotiabank Raises Target Price to $48 From $45

THOMSON REUTERS
·
25 Nov 2024

BridgeBio Pharma Inc : Leerink Partners Raises Target Price to $47 From $46

THOMSON REUTERS
·
25 Nov 2024

BridgeBio announces FDA approved Attruby for ATTR-CM patients

TIPRANKS
·
23 Nov 2024

US FDA approves BridgeBio's drug for rare heart condition

Reuters
·
23 Nov 2024

BRIEF-AttrubyA Approved By FDA To Reduce Cardiovascular Death And Cardiovascular-Related Hospitalization In Attr-Cm Patients

Reuters
·
23 Nov 2024

Attruby™ (Acoramidis), a Near Complete Ttr Stabilizer (≥90%), Approved by FDA to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Attr-Cm Patients

THOMSON REUTERS
·
23 Nov 2024

BridgeBio Pharma Inc - FDA Approves Attruby for Treatment of Attr-Cm

THOMSON REUTERS
·
23 Nov 2024

BridgeBio Pharma Inc - Grants Bayer Rights to Commercialize Acoramidis in Europe

THOMSON REUTERS
·
23 Nov 2024

BridgeBio Pharma Inc - to Receive $500 Million Payment Under Royalty Agreement

THOMSON REUTERS
·
23 Nov 2024

BridgeBio Pharma trading halted, news pending

TIPRANKS
·
23 Nov 2024

BridgeBio Pharma call volume above normal and directionally bullish

TIPRANKS
·
22 Nov 2024

J.P. Morgan Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

TIPRANKS
·
21 Nov 2024

U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, Walmart

Reuters
·
20 Nov 2024

BridgeBio Pharma Inc : JP Morgan Cuts Target Price to $40 From $43

THOMSON REUTERS
·
20 Nov 2024

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

Benzinga
·
20 Nov 2024

The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically

Simply Wall St.
·
19 Nov 2024

Stock Track | BridgeBio Pharma Plummets 5.06% as Trial Data Disappoints

Stock Track
·
19 Nov 2024

BRIEF-Bridgebio Pharma Says Acoramidis Well Tolerated With No New Safety Signals In Long-Term Evaluation

Reuters
·
19 Nov 2024